HLA-DRB1 alleles and genotypes in patients with relapsing-remitting multiple sclerosis from western Mexico: a pilot study

被引:0
|
作者
Alfonso Cruz-Ramos, Jose [1 ,2 ,3 ]
Gabriel Ortiz, Genaro [1 ,2 ,3 ]
Ignacio Diaz-Barba, Eduardo [1 ,2 ,3 ]
Angel Macias-Islas, Miguel [4 ]
Mireles-Ramirez, Mario [4 ]
机构
[1] IMSS, CIBO, Lab Desarrollo Envejecimiento, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico
[2] IMSS, CIBO, Enfermedades Neurodegenerat, Sierra Mojada 800, Guadalajara 44340, Jalisco, Mexico
[3] IMSS, CIBO, Div Neurociencias, Guadalajara, Jalisco, Mexico
[4] IMSS, CMNO, Hosp Especialidades, UMAE,Dept Neurol, Guadalajara, Jalisco, Mexico
来源
INVESTIGACION CLINICA | 2017年 / 58卷 / 04期
关键词
HLA-DRB1; relapsing-remitting multiple sclerosis; risk; alleles; genotypes; Mexican mestizo; CLASS-II ALLELES; MESTIZO POPULATION; HLA; RISK; SUSCEPTIBILITY; HAPLOTYPES; RESISTANCE; ADMIXTURE; THERAPY; MARKERS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The HLA-DRB1 alleles are closely related to genetic susceptibility to multiple sclerosis (MS). There is a high prevalence of MS in Caucasian populations, whereas non-Caucasian populations have a low prevalence. In Latin American countries, genomes are made up of a heterogeneous gene pool, which varies between different regions of each country. The objective of this study was to evaluate the association of alleles and genotypes of HLA-DRBI in relapsing-remitting multiple sclerosis (RRMS) in Mexican Mestizos of western Mexico. HLA-DRB1 alleles and genotypes were determined for 59 RRMS patients and 434 healthy subjects. The results show that allele HLA-DRB1*15 (p: 0.013, OR: 2.74) was associated with risk of RRMS, no others alleles were significantly associated. Whereas, a risk tendency was observed for alleles HLA-DRB1*09 (p: 0.062, OR: 6.24), HLA-DRB1*04 (p: 0.086, OR: 1.876) and genotypes HLA-DRf31*15/*13 (p: 0.068, OR: 15.71), HLA-DRBI*15/*04 (p: 0.068, OR: 6.35). Otherwise, the alleles HLA-DRB1*08 (p: 0.062, OR: 0.340) and HLA-DRB1*01(p: 0.062, OR: 0.29) show tendency to a protective effect. Further research is required about risk alleles in larger patient RRMS cohorts in western Mexico. HLA-DRBI risk allelic variation in different regions of Mexico for MS further illustrates the genetic heterogeneity of the Mexican population and the Caucasian influence in shaping the epidemiology of MS in Mexico.
引用
收藏
页码:323 / 333
页数:11
相关论文
共 50 条
  • [21] Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis
    Esposito, Federica
    Radaelli, Marta
    Martinelli, Vittorio
    Sormani, Maria Pia
    Boneschi, Filippo Martinelli
    Moiola, Lucia
    Rocca, Maria Assunta
    Rodegher, Mariaemma
    Comi, Giancarlo
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (12) : 1490 - 1499
  • [22] Study of the frequency of HLA-DRB1 alleles in Brazilian patients with rheumatoid arthritis
    Gomez Usnayo, Magali Justina
    Coelho Andrade, Luis Eduardo
    Alarcon, Renata Triguenho
    Oliveira, Juliana Cardoso
    Fabricio Silva, Gustavo Milson
    Bendet, Izidro
    Burlingame, Rufus
    Porto, Luis Cristovao
    Castelar Pinheiro, Geraldo da Rocha
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2011, 51 (05) : 465 - 483
  • [23] HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population
    Romero-Pinel, L.
    Pujal, J. M.
    Martinez-Yelamos, S.
    Gubieras, L.
    Matas, E.
    Bau, L.
    Torrabadella, M.
    Azqueta, C.
    Arbizu, T.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 (02) : 337 - 342
  • [24] Vitamin D and disability in relapsing-remitting multiple sclerosis in patients with a Mexican background
    Rito, Yamel
    Flores, Jesus
    Fernandez-Aguilar, Angeles
    Escalante-Membrillo, Carmen
    Barboza, Miguel A.
    Amezcua, Lilyana
    Corona, Teresa
    ACTA NEUROLOGICA BELGICA, 2018, 118 (01) : 47 - 52
  • [25] Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
    Onder, Halil
    TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (02) : 105 - 106
  • [26] Comorbidity in in patients with relapsing-remitting multiple sclerosis.
    Somilo, O., V
    Makarov, S. O.
    Kalbus, O., I
    MEDICNI PERSPEKTIVI, 2024, 29 (03): : 137 - 143
  • [27] Multiple sclerosis, vitamin D, and HLA-DRB1*15
    Handunnetthi, Lahiru
    Ramagopalan, Sreeram V.
    Ebers, George C.
    NEUROLOGY, 2010, 74 (23) : 1905 - 1910
  • [28] HLA-DRB1*15:03 and HLA-DRB1*11: useful predictive alleles for alloantibody production in thalassemia patients
    Darvishi, P.
    Sharifi, Z.
    Azarkeivan, A.
    Akbari, A.
    Pourfathollah, A. A.
    TRANSFUSION MEDICINE, 2019, 29 (03) : 179 - 184
  • [29] Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study
    Riccio, Paolo
    Rossano, Rocco
    Larocca, Marilena
    Trotta, Vincenzo
    Mennella, Ilario
    Vitaglione, Paola
    Ettorre, Michele
    Graverini, Antonio
    De Santis, Alessandro
    Di Monte, Elisabetta
    Coniglio, Maria Gabriella
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 241 (06) : 620 - 635
  • [30] Folate receptor alpha autoantibodies in the serum of patients with relapsing-remitting multiple sclerosis (RRMS)
    Mashayekhi, Farhad
    Hadipour, Elham
    Shabani, Somayeh
    Salehi, Zivar
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2024, 237